Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated parkinson disease

Neurology

Volumn 80, Issue 7, 2013, Pages 621-626

  Sierra, Maria ^a   Sánchez Juan, Pascual ^a   Martínez Rodríguez, María Isabel ^a   González Aramburu, Isabel ^a   García Gorostiaga, Inés ^b   Quirce, María Remedios ^a   Palacio, Enrique ^a   Carril, José Manuel ^a   Berciano, José ^a   Combarros, Onofre ^a   Infante, Jon ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL DE GALDAKAO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE TRANSPORTER; IOFLUPANE I 123; LEUCINE RICH REPEAT KINASE 2; GLYCINE; IOFLUPANE; LRRK2 PROTEIN, HUMAN; NORTROPANE DERIVATIVE; PROTEIN SERINE THREONINE KINASE; SERINE;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; GAMMA CAMERA; GENE; GENE MUTATION; GENETIC ASSOCIATION; GROUPS BY AGE; HETEROZYGOTE; HUMAN; HYPOSMIA; LRRK2 GENE; MALE; NEUROIMAGING; NEUROPATHOLOGY; PARKINSON DISEASE; PREMOTOR CORTEX; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMELLING; SUBSTANTIA NIGRA; ULTRASOUND SCANNER; AGED; CHI SQUARE DISTRIBUTION; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DOPPLER ECHOGRAPHY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; ODOR; PATHOLOGY; SCINTISCANNING; SEVERITY OF ILLNESS INDEX; SMELLING DISORDER;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLYCINE; HUMANS; MALE; MIDDLE AGED; MUTATION; NORTROPANES; OLFACTION DISORDERS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SERINE; SEVERITY OF ILLNESS INDEX; SMELL; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

MLCS; MLOWN;

EID: 84875866982     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31828250d6     Document Type: Article

References (24)

1. Healy DG, Falchi M, O'Sullivan SS, et al; International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-590.
2. Marras C, Schüle B, Munhoz RP, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011;77:325-333.
3. Brockmann K, Gröger A, Di Santo A, et al. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 2011;26:2335-2342.
4. Goldwurm S, Zini M, Mariani L, et al. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology 2007;68:1141-1143.
5. Sierra M, González-Aramburu I, Sánchez-Juan P, et al. High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain). Mov Disord 2011;26:2343-2346.
6. Litvan I, Bhatia KP, Burn DJ, et al; Movement Disorders Society Scientific Issues Committee. Movement disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003;18:467-486.
7. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738-750.
8. Doty RL. The Smell Identification Test Administration Manual, 3rd ed. Haddon Heights, NJ: Sensonics; 1995.
9. Brüggemann N, Hagenah J, Stanley K, et al. Substantia nigra hyperechogenicity with LRRK2 G2019S mutations. Mov Disord 2011;26:885-888.
10. Schweitzer KJ, Behnke S, Liepelt I, et al. Cross-sectional study discloses a positive family history for Parkinson's disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity. J Neural Transm 2007;114:1167-1171.
11. Mehnert S, Reuter I, Schepp K, Maaser P, Stolz E, Kaps M. Transcranial sonography for diagnosis of Parkinson's disease. BMC Neurol 2010;10:9.
12. Berg D. Transcranial ultrasound as a risk marker for Parkinson's disease. Mov Disord 2009;24:S677-S683.
13. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 2005;20:383-385.
14. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson's disease. Parkinsonism Relat Disord 2007;13(suppl): S2-S7.
15. Hawkes C. Olfaction in neurodegenerative disorder. Mov Disord 2003;18:364-372.
16. Del Tredici K, Braak H. Lewy pathology and neurodegeneration in premotor Parkinson's disease. Mov Disord 2012;27:597-607.
17. Bohnen NI, Müller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 2010;133:1747-1754.
18. Saunders-Pullman R, Stanley K, Wang C, et al. Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology 2011;77:319-324.
19. Ruiz-Martínez J, Gorostidi A, Goyenechea E, et al. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations. Mov Disord 2011;26:2026-2031.
20. Silveira-Moriyama L, Munhoz RP, de J Carvalho M, et al. Olfactory heterogeneity in LRRK2 related Parkinsonism. Mov Disord 2010;25:2879-2883.
21. Lohmann E, Leclere L, De Anna F, et al; French Parkinson's Disease Genetics Study Group. A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations. Parkinsonism Relat Disord 2009;15:273-276.
22. Valldeoriola F, Gaig C, Muxí A, et al. 123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations. J Neurol 2011;258:1126-1132.
23. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
24. Berg D, Marek K, Ross GW, Poewe W. Defining at-risk populations for Parkinson's disease: lessons from ongoing studies. Mov Disord 2012;27:656-665.